{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiexnrw7gf3v3n5pt2o4usma7h6clivjdmkrgmxeie64avijebwyp4",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mkqt4xdsy7a2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiakxbjruwwr6c3olb6r3q43p3lxch7urgbzqhybsn2o7hbzkitmoi"
    },
    "mimeType": "image/jpeg",
    "size": 145661
  },
  "path": "/news/2026-04-glp-heavy-days-treatment-people.html",
  "publishedAt": "2026-04-30T18:30:05.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A trial of 108 adults with obesity seeking treatment for alcohol use finds a once-weekly semaglutide injection reduced heavy drinking days in the past 30 days by an average of roughly 12 days, 50% higher than the eight-day reduction seen in the placebo group. The study is published in The Lancet.",
  "title": "GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial"
}